Compare CIA & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIA | HELP |
|---|---|---|
| Founded | 1969 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.0M | 249.0M |
| IPO Year | 1995 | N/A |
| Metric | CIA | HELP |
|---|---|---|
| Price | $5.41 | $5.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $51.50 |
| AVG Volume (30 Days) | 115.4K | ★ 625.6K |
| Earning Date | 05-07-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $255,616,000.00 | N/A |
| Revenue This Year | $3.10 | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $28.23 | ★ N/A |
| Revenue Growth | ★ 4.33 | N/A |
| 52 Week Low | $3.25 | $4.29 |
| 52 Week High | $6.40 | $8.55 |
| Indicator | CIA | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 56.51 | 53.34 |
| Support Level | $5.10 | $4.40 |
| Resistance Level | $5.50 | $8.55 |
| Average True Range (ATR) | 0.26 | 0.30 |
| MACD | 0.09 | 0.15 |
| Stochastic Oscillator | 77.11 | 87.50 |
Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States. The company provides insurance benefits to residents in thirty two U.S. states and more than seventy countries through its insurance subsidiaries. The company operates in two business segments namely the Life Insurance segment and the Home Service Insurance segment. The company majority generates revenues from Life Insurance segment. Company operates in USA, Columbia, Taiwan, Venezuela, Ecuador, Argentina, and Others.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.